Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study comparing safety and efficacy of obinutuzumab with rituximab in relapsed indolent lymphoma. The primary end point of this study was the overall response rate (ORR) in patients with follicular lymphoma after induction and safety in patients with indolent lymphoma.
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study / Sehn, Laurie H; Goy, Andre; Offner, Fritz C; Martinelli, Giovanni; Caballero, M Dolores; Gadeberg, Ole; Baetz, Tara; Zelenetz, Andrew D; Gaidano, Gianluca; Fayad, Luis E; Buckstein, Rena; Friedberg, Jonathan W; Crump, Michael; Jaksic, Branimir; Zinzani, Pier Luigi; Padmanabhan Iyer, Swaminathan; Sahin, Deniz; Chai, Akiko; Fingerle-Rowson, Günter; Press, Oliver W. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 33:30(2015), pp. 3467-3474. [10.1200/JCO.2014.59.2139]
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
MARTINELLI, GIOVANNI;ZINZANI, PIER LUIGI;
2015
Abstract
Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study comparing safety and efficacy of obinutuzumab with rituximab in relapsed indolent lymphoma. The primary end point of this study was the overall response rate (ORR) in patients with follicular lymphoma after induction and safety in patients with indolent lymphoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
